Vepalimomab
Vepalimomab
Vepalimomab (pronunciation: ve-pa-li-mo-mab) is a novel monoclonal antibody designed for the treatment of various autoimmune diseases.
Etymology
The name "Vepalimomab" follows the World Health Organization's guidelines for the International Nonproprietary Names (INN) of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-limo-" suggests its immunomodulating function.
Function
Vepalimomab works by binding to specific proteins in the body that are involved in the immune response. By doing so, it can help to reduce inflammation and other symptoms associated with autoimmune diseases.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Inflammation: A localized physical condition in which part of the body becomes reddened, swollen, hot, and often painful, especially as a reaction to injury or infection.
- Immunomodulating: Modifying the immune response or the functioning of the immune system (as by the stimulation of antibody formation or the inhibition of white blood cell activity).
See Also
External links
- Medical encyclopedia article on Vepalimomab
- Wikipedia's article - Vepalimomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski